NEW YORK, Feb. 5, 2019 Aetion, the health care technology company that delivers the real-world analytics and evidence platform needed to engage in value-based care, announced it has attracted strategic investment from global leaders in biopharma and health care services, including Sanofi, UCB, McKesson Ventures, and Horizon Health Services, Inc., a Blue Cross Blue Shield of New Jersey company — four new strategic shareholders that join Amgen Ventures, an earlier investor. Existing venture capital investors also participated in this round, including NEA, Flare Capital, and Lakestar.
The latest strategic capital infusion of $27 million reflects Aetion's substantial growth in customer adoption over the past year. Coupled with its prior funding in early 2018, the investment caps the total Series B funding at $63 million. This brings Aetion's total funding to $77 million since its 2015 launch. Investment funds will be applied to strengthen the Aetion Evidence Platform™, extending its reach in therapeutic area-related intelligence, outcomes-based contracting for payers, and advancing the acceptance of standards for real-world evidence around the globe.
"The time for real-world evidence is now," said Carolyn Magill, Chief Executive Officer of Aetion. "We're entering a new era in which nearly the entire health care ecosystem — from biopharma and regulators to payers and technology companies — recognizes the importance of using real-world evidence to reduce the time and cost to bring new therapies to market. This funding demonstrates that the industry's leaders, who are using our technology to drive health care's most critical decisions, view Aetion as a trusted partner vital to their long-term success."
For Aetion, strategic backing from a sweep of biopharma, health care services, and payer organizations with investment capital reinforces its position as an unbiased thought-leader at the forefront of industry adoption of real-world evidence, and underscores growing confidence among its partners and clients in the Aetion Evidence Platform as the analytics tool of record.
"We are at an inflection point, in which the convergence of massive analytical advances and enormous amounts of new data are transforming what's possible in health care," said Ameet Nathwani, M.D., Chief Medical Officer at Sanofi. "Aetion is ideally positioned to lead this shift, given the power of its technology and extensive experience with biopharma leaders and the FDA. Sanofi is excited to join as a strategic investor as the company helps set the global standards for real-world evidence."
“Now we're asking an industry to reflect and think strategically about how to position itself in a value-driven industry. That's the impetus for the change we're going through.”
Barbara Anyone VP , Marketing, Company, Inc.
Aetion is a health care technology company that delivers real-world evidence for life sciences, payers, providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce transparent, rapid, and scientifically validated answers on treatments, costs, and outcomes. Founded by Harvard Medical School faculty members with decades of experience in epidemiology and health outcomes research, Aetion informs health care's most critical decisions — what works best, for whom, and when — to guide treatment development, commercialization, and payment innovation into health care's modern era.
Aetion is based in New York City, and backed by investors including New Enterprise Associates (NEA), Flare Capital Partners, Lakestar, Town Hall Ventures, McKesson Ventures, Sanofi Ventures, Amgen Ventures, UCB, and Horizon Health Services, Inc. Learn more at aetion.com, and follow us at @aetioninc.
Source: Aetion
Related Links: aetion.com